Načítá se...
Predictors of negotiated prices for new drugs in Germany
INTRODUCTION: In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of new, n...
Uloženo v:
| Vydáno v: | Eur J Health Econ |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7423852/ https://ncbi.nlm.nih.gov/pubmed/32451745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10198-020-01201-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|